Effects of a Short Course of Oral Prednisolone in Patients with Bladder Pain Syndrome with Fluctuating, Worsening Pain despite Low-Dose Triple Therapy.
- Author:
Hee Jong JEONG
1
Author Information
1. Department of Urology, Wonkwang University School of Medicine & Hospital, Iksan, Korea. uro94c@wku.ac.kr
- Publication Type:Original Article
- Keywords:
Interstitial cystitis;
Pain measurement;
Adrenal cortex hormones
- MeSH:
Adrenal Cortex Hormones;
Amines;
Amitriptyline;
Cyclohexanecarboxylic Acids;
Cystitis;
Cystitis, Interstitial;
Female;
gamma-Aminobutyric Acid;
Humans;
Outcome Assessment (Health Care);
Pain Measurement;
Prednisolone;
Sperm Injections, Intracytoplasmic;
Urinary Bladder
- From:International Neurourology Journal
2012;16(4):175-180
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Triple therapy with gabapentin, amitriptyline, and nonsteroidal antiinflammatory drugs is efficacious for chronic bladder pain syndrome/interstitial cystitis (BPS/IC). However, transient, fluctuating, worsening pain or flare-up symptoms may develop during treatment for a variety of reasons. Here, we assessed the validity of our observational experience regarding a short course of oral prednisolone therapy, which might be of value in the management of flare-up symptoms of BPS/IC. METHODS: Between May 2007 and May 2012, 7 women (mean age, 61.5 years; range, 44.8 to 75.4 years) with BPS/IC presenting with transient, fluctuating, worsening pain as a flare-up symptom despite low-dose triple therapy received a 1- to 3-month course of oral prednisolone 10 mg. The outcome measures used were the IC symptom scale (ICSS, O'Leary-Sant Interstitial Cystitis Symptom Index) and a visual analogue scale (VAS), which were completed at baseline and after treatment. RESULTS: There were statistically significant differences in the ICSS and VAS score before and after prednisolone treatment (P<0.05 by Wilcoxon singed-rank test). The pretreatment IC symptom index (ICSI), IC problem index (ICPI), and VAS score were 16.7+/- 2.2, 13.7+/-2.3, and 8.3+/-1.5 (mean+/-standard deviation [SD]), and the posttreatment scores were 4.9+/-2.3, 4.3+/-1.1, and 2.5+/-0.9 (mean+/-SD), respectively. The ICSI, ICPI, and VAS scores were improved after prednisolone treatment by 70.7%, 68.6%, and 69.9%, respectively. Low-dose triple therapy with prednisolone caused no significant adverse effects. CONCLUSIONS: In patients with BPS/IC who show transient, fluctuating, worsening pain as flare-up symptoms despite undergoing low-dose triple therapy, a short course of oral prednisolone therapy was sufficiently effective. However, large-scale studies should be performed to verify our findings.
